The peptide-drug landscape is becoming more competitive: Zealand Pharma (in partnership with Roche) announced strategic plans to launch a pipeline of metabolic and obesity-focused peptide drugs, including candidates designed to address side-effect profiles and long-term use. Reuters➡️ Competition of this scale indicates not only strong market growth, but also innovation in peptide modalities beyond existing GLP-1 approaches.







